X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AUROBINDO PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AUROBINDO PHARMA GLENMARK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 13.9 18.0 77.1% View Chart
P/BV x 3.9 5.8 66.4% View Chart
Dividend Yield % 0.3 0.4 92.2%  

Financials

 GLENMARK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
AUROBINDO PHARMA
Mar-16
GLENMARK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2621,541 81.9%   
Low Rs672582 115.4%   
Sales per share (Unadj.) Rs270.6237.5 113.9%  
Earnings per share (Unadj.) Rs24.933.9 73.4%  
Cash flow per share (Unadj.) Rs34.440.6 84.8%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.20.2 87.8%  
Book value per share (Unadj.) Rs151.3120.6 125.5%  
Shares outstanding (eoy) m282.16585.17 48.2%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x3.64.5 80.0%   
Avg P/E ratio x38.931.3 124.0%  
P/CF ratio (eoy) x28.126.2 107.4%  
Price / Book Value ratio x6.48.8 72.6%  
Dividend payout %8.07.4 108.9%   
Avg Mkt Cap Rs m272,778621,041 43.9%   
No. of employees `00010.013.3 75.4%   
Total wages/salary Rs m13,78215,508 88.9%   
Avg. sales/employee Rs Th7,614.910,457.6 72.8%   
Avg. wages/employee Rs Th1,374.81,167.1 117.8%   
Avg. net profit/employee Rs Th700.21,491.6 46.9%   
INCOME DATA
Net Sales Rs m76,340138,961 54.9%  
Other income Rs m3561,663 21.4%   
Total revenues Rs m76,696140,624 54.5%   
Gross profit Rs m14,17232,056 44.2%  
Depreciation Rs m2,6913,926 68.6%   
Interest Rs m1,7892,568 69.7%   
Profit before tax Rs m10,04827,225 36.9%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,0287,444 40.7%   
Profit after tax Rs m7,01919,820 35.4%  
Gross profit margin %18.623.1 80.5%  
Effective tax rate %30.127.3 110.2%   
Net profit margin %9.214.3 64.5%  
BALANCE SHEET DATA
Current assets Rs m59,096100,015 59.1%   
Current liabilities Rs m40,01874,759 53.5%   
Net working cap to sales %25.018.2 137.5%  
Current ratio x1.51.3 110.4%  
Inventory Days Days75107 69.8%  
Debtors Days Days119110 108.8%  
Net fixed assets Rs m39,07552,350 74.6%   
Share capital Rs m282585 48.2%   
"Free" reserves Rs m30,28167,707 44.7%   
Net worth Rs m42,70370,567 60.5%   
Long term debt Rs m24,8738,472 293.6%   
Total assets Rs m111,026156,994 70.7%  
Interest coverage x6.611.6 57.0%   
Debt to equity ratio x0.60.1 485.2%  
Sales to assets ratio x0.70.9 77.7%   
Return on assets %7.914.3 55.6%  
Return on equity %16.428.1 58.5%  
Return on capital %17.537.7 46.4%  
Exports to sales %43.351.0 84.8%   
Imports to sales %7.418.8 39.4%   
Exports (fob) Rs m33,04470,927 46.6%   
Imports (cif) Rs m5,67226,193 21.7%   
Fx inflow Rs m36,94571,015 52.0%   
Fx outflow Rs m61,06628,799 212.0%   
Net fx Rs m-24,12242,216 -57.1%   
CASH FLOW
From Operations Rs m3,44917,596 19.6%  
From Investments Rs m-8,802-13,801 63.8%  
From Financial Activity Rs m6,986-198 -3,522.9%  
Net Cashflow Rs m9343,597 26.0%  

Share Holding

Indian Promoters % 48.3 54.1 89.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.0 86.8%  
FIIs % 34.4 27.7 124.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   56,727 69,601 81.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS